Analysts Set Teleflex Incorporated (NYSE:TFX) Price Target at $141.57

Teleflex Incorporated (NYSE:TFX) has been assigned an average recommendation of “Reduce” from the twelve research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $141.5714.

Several equities analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Teleflex in a report on Wednesday, October 8th. Mizuho increased their price objective on shares of Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a research note on Friday, August 1st. Wells Fargo & Company decreased their target price on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. Wall Street Zen downgraded Teleflex from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 15th. Finally, Royal Bank Of Canada boosted their price objective on Teleflex from $130.00 to $135.00 and gave the company a “sector perform” rating in a report on Friday, August 1st.

Insiders Place Their Bets

In other news, Director Andrew A. Krakauer acquired 1,000 shares of the company’s stock in a transaction dated Tuesday, August 5th. The shares were acquired at an average price of $115.25 per share, with a total value of $115,250.00. Following the purchase, the director directly owned 7,192 shares of the company’s stock, valued at $828,878. This trade represents a 16.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Stuart A. Randle bought 1,000 shares of the business’s stock in a transaction dated Tuesday, August 5th. The shares were purchased at an average cost of $115.86 per share, with a total value of $115,860.00. Following the completion of the acquisition, the director owned 7,547 shares in the company, valued at approximately $874,395.42. This represents a 15.27% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 5,500 shares of company stock worth $633,590. Corporate insiders own 1.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Teacher Retirement System of Texas purchased a new position in shares of Teleflex in the 1st quarter valued at about $1,242,000. Amalgamated Bank grew its holdings in Teleflex by 56.9% in the first quarter. Amalgamated Bank now owns 14,046 shares of the medical technology company’s stock valued at $1,941,000 after purchasing an additional 5,095 shares during the period. New York State Teachers Retirement System increased its position in shares of Teleflex by 13.9% in the first quarter. New York State Teachers Retirement System now owns 45,063 shares of the medical technology company’s stock valued at $6,227,000 after buying an additional 5,482 shares in the last quarter. NorthCrest Asset Manangement LLC purchased a new stake in shares of Teleflex in the second quarter valued at approximately $299,000. Finally, Brown Advisory Inc. raised its stake in shares of Teleflex by 34.2% during the 1st quarter. Brown Advisory Inc. now owns 2,524 shares of the medical technology company’s stock worth $349,000 after buying an additional 643 shares during the period. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Stock Performance

Shares of TFX stock opened at $132.06 on Tuesday. The business has a fifty day moving average of $126.06 and a 200 day moving average of $123.65. Teleflex has a 1 year low of $108.90 and a 1 year high of $239.46. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. The firm has a market capitalization of $5.84 billion, a price-to-earnings ratio of 31.07, a price-to-earnings-growth ratio of 1.85 and a beta of 1.05.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The business had revenue of $780.90 million for the quarter, compared to analyst estimates of $771.53 million. During the same period in the prior year, the company earned $3.42 earnings per share. The company’s revenue was up 4.2% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. As a group, research analysts expect that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 15th. Shareholders of record on Friday, August 15th were issued a $0.34 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. Teleflex’s payout ratio is presently 32.00%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.